PMID- 29617171
OWN - NLM
STAT- MEDLINE
DCOM- 20180510
LR  - 20190221
IS  - 1744-7607 (Electronic)
IS  - 1742-5255 (Linking)
VI  - 14
IP  - 4
DP  - 2018 Apr
TI  - Lenvatinib-induced renal failure: two first-time case reports and review of 
      literature.
PG  - 379-385
LID - 10.1080/17425255.2018.1461839 [doi]
AB  - Lenvatinib (LEN) is a multi-kinase anti-angiogenic drug recently approved in 
      several cancers. LEN is not easily manageable due to its complex safety profile. 
      Proteinuria and renal failure (RF) were reported among the most frequent 
      LEN-induced adverse events (AEs), often leading to discontinuations or dose 
      modifications. Understanding the pathogenesis of these AEs could ameliorate the 
      management of LEN-induced renal toxicity. Areas covered: We present two cases of 
      LEN-induced renal failure (LIRF) with different pathogenesis. 1) LIRF with severe 
      proteinuria in a man treated for a metastatic papillary thyroid carcinoma. Kidney 
      biopsy showed a glomerular damage secondary to LEN, having excluded other causes 
      of RF. 2) LIRF without proteinuria in a woman with metastatic adenoid cystic 
      carcinoma of minor salivary gland. A tubulointerstitial nephropathy was supposed 
      by clinical evaluation and laboratory tests. Effective management was obtained by 
      oral steroids without interrupting LEN. Expert opinion: The case 1 presented for 
      the first time the histological picture of LIRF with a classical glomerular 
      damage leading to secondary proteinuria and tubular failure. Case 2 showed an 
      alternative LIRF pattern of likely tubulointerstitial injury without proteinuria. 
      These reports reflect two sides of the same coin, both to be considered in case 
      of LIRF.
FAU - Cavalieri, Stefano
AU  - Cavalieri S
AD  - a Head and Neck Cancer Medical Oncology 3 Department , Fondazione IRCCS Istituto 
      Nazionale dei Tumori , Milan , Italy.
FAU - Cosmai, Laura
AU  - Cosmai L
AD  - b Nephrology Unit , ASST Santi Paolo e Carlo , Milan , Italy.
FAU - Genderini, Augusto
AU  - Genderini A
AD  - c Nephrology Unit , ASST Fatebenefratelli - Luigi Sacco , Milan , Italy.
FAU - Nebuloni, Manuela
AU  - Nebuloni M
AD  - d Pathology Unit , ASST Fatebenefratelli - Luigi Sacco , Milan , Italy.
FAU - Tosoni, Antonella
AU  - Tosoni A
AD  - d Pathology Unit , ASST Fatebenefratelli - Luigi Sacco , Milan , Italy.
FAU - Favales, Federica
AU  - Favales F
AD  - a Head and Neck Cancer Medical Oncology 3 Department , Fondazione IRCCS Istituto 
      Nazionale dei Tumori , Milan , Italy.
FAU - Pistillo, Paola
AU  - Pistillo P
AD  - a Head and Neck Cancer Medical Oncology 3 Department , Fondazione IRCCS Istituto 
      Nazionale dei Tumori , Milan , Italy.
FAU - Bergamini, Cristiana
AU  - Bergamini C
AD  - a Head and Neck Cancer Medical Oncology 3 Department , Fondazione IRCCS Istituto 
      Nazionale dei Tumori , Milan , Italy.
FAU - Bossi, Paolo
AU  - Bossi P
AD  - a Head and Neck Cancer Medical Oncology 3 Department , Fondazione IRCCS Istituto 
      Nazionale dei Tumori , Milan , Italy.
FAU - Licitra, Lisa
AU  - Licitra L
AD  - a Head and Neck Cancer Medical Oncology 3 Department , Fondazione IRCCS Istituto 
      Nazionale dei Tumori , Milan , Italy.
AD  - e Department of Oncology , University of Milan , Milan , Italy.
FAU - Locati, Laura D
AU  - Locati LD
AD  - a Head and Neck Cancer Medical Oncology 3 Department , Fondazione IRCCS Istituto 
      Nazionale dei Tumori , Milan , Italy.
FAU - Alfieri, Salvatore
AU  - Alfieri S
AD  - a Head and Neck Cancer Medical Oncology 3 Department , Fondazione IRCCS Istituto 
      Nazionale dei Tumori , Milan , Italy.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20180413
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Quinolines)
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/administration & dosage/*adverse effects
MH  - Carcinoma, Adenoid Cystic/drug therapy
MH  - Carcinoma, Papillary/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenylurea Compounds/administration & dosage/*adverse effects
MH  - Proteinuria/etiology
MH  - Quinolines/administration & dosage/*adverse effects
MH  - Renal Insufficiency/*chemically induced
MH  - Salivary Gland Neoplasms/drug therapy
MH  - Thyroid Cancer, Papillary
MH  - Thyroid Neoplasms/drug therapy
OTO - NOTNLM
OT  - Antiangiogenic
OT  - VEGF
OT  - VEGFR
OT  - lenvatinib
OT  - nephropathy
OT  - proteinuria
OT  - renal failure
OT  - salivary gland cancer
OT  - thyroid cancer
OT  - toxicity
EDAT- 2018/04/05 06:00
MHDA- 2018/05/11 06:00
CRDT- 2018/04/05 06:00
PHST- 2018/04/05 06:00 [pubmed]
PHST- 2018/05/11 06:00 [medline]
PHST- 2018/04/05 06:00 [entrez]
AID - 10.1080/17425255.2018.1461839 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):379-385. doi: 
      10.1080/17425255.2018.1461839. Epub 2018 Apr 13.